Objective Assessment of Disparity Vergence after Treatment of Symptomatic Convergence Insufficiency in Children.


Journal

Optometry and vision science : official publication of the American Academy of Optometry
ISSN: 1538-9235
Titre abrégé: Optom Vis Sci
Pays: United States
ID NLM: 8904931

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 21 12 2018
medline: 21 12 2019
entrez: 21 12 2018
Statut: ppublish

Résumé

This first report of the use of objective measures of disparity vergence as outcome measures for symptomatic convergence insufficiency in children provides additional information that is not accessible with clinical tests. The study results also demonstrate that objective measures of vergence could be used in future randomized clinical trials of binocular vision disorders with children. This study was designed to evaluate changes in objective measures of disparity vergence after office-based vergence/accommodative therapy (OBVAT) for convergence insufficiency in children 12 to 17 years old. In this prospective trial, we recruited 10 participants with normal binocular vision and 12 with convergence insufficiency. All participants with convergence insufficiency were treated with 12 weeks of OBVAT. The primary outcome measure was average peak velocity for 4° symmetrical convergence steps. Other objective outcome measures of disparity vergence included time to peak velocity, latency, and accuracy. Changes in clinical measures (near point of convergence, positive fusional vergence at near) and symptoms were evaluated. There was a statistically significant increase in peak velocity and more accurate response amplitude to 4° symmetrical convergence step stimuli after OBVAT compared with baseline measurements. Near point of convergence, positive fusional vergence, and symptoms also statistically significantly improved after OBVAT. Ten of the 12 participants met clinical success criteria. In this prospective study on the treatment of symptomatic convergence insufficiency in children in which both clinical and objective eye movement measurements were used to evaluate the results of treatment, significant changes were found in symptoms and both clinical and objective measures of disparity vergence after completion of OBVAT in children with symptomatic convergence insufficiency.

Identifiants

pubmed: 30570596
doi: 10.1097/OPX.0000000000001320
pmc: PMC6305249
mid: NIHMS1509307
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

3-16

Subventions

Organisme : NEI NIH HHS
ID : R01 EY023261
Pays : United States

Références

Exp Brain Res. 2004 Aug;157(3):286-95
pubmed: 15024539
Optom Vis Sci. 2010 Dec;87(12):E985-1002
pubmed: 21057347
Optom Vis Sci. 1992 Apr;69(4):258-69
pubmed: 1565425
Vision Res. 2012 Jun 1;62:93-101
pubmed: 22480879
Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4017-27
pubmed: 20335602
Arch Ophthalmol. 2005 Apr;123(4):437-47
pubmed: 15824215
Biol Cybern. 1982;45(1):1-4
pubmed: 7126687
Optom Vis Sci. 2017 Jan;94(1):74-88
pubmed: 27464574
Transl Vis Sci Technol. 2016 Mar 11;5(2):8
pubmed: 26981330
Vision Res. 1986;26(6):927-42
pubmed: 3750876
J Ophthalmol. 2016;2016:6963976
pubmed: 27525112
Optometry. 2003 Jan;74(1):25-34
pubmed: 12539890
Vision Res. 1987;27(10):1797-806
pubmed: 3445469
Am J Optom Physiol Opt. 1985 Jun;62(6):369-74
pubmed: 4014424
Optom Vis Sci. 1999 Sep;76(9):643-9
pubmed: 10498006
Optom Vis Sci. 2012 Oct;89(10):1512-20
pubmed: 22922781
Front Integr Neurosci. 2016 Oct 20;10:33
pubmed: 27812325
Optom Vis Sci. 2009 Apr;86(4):357-63
pubmed: 19289977
Vision Res. 1994 Apr;34(8):1077-87
pubmed: 8160416
Conf Proc IEEE Eng Med Biol Soc. 2011;2011:1664-7
pubmed: 22254644
Ophthalmic Epidemiol. 2008 Jan-Feb;15(1):24-36
pubmed: 18300086
Optom Vis Sci. 2003 Dec;80(12):832-8
pubmed: 14688547
Br J Ophthalmol. 2005 Oct;89(10):1318-23
pubmed: 16170124
Front Integr Neurosci. 2014 Jun 17;8:50
pubmed: 24987340
Am J Optom Physiol Opt. 1980 Sep;57(9):559-65
pubmed: 7425078
Clin Exp Optom. 2017 Nov;100(6):642-648
pubmed: 27859646
IEEE Trans Biomed Eng. 1980 Aug;27(8):439-47
pubmed: 7409812
Am J Optom Physiol Opt. 1986 Aug;63(8):645-53
pubmed: 3766694
Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):329-342
pubmed: 28114594
J Optom. 2016 Oct-Dec;9(4):246-57
pubmed: 26750804
Cochrane Database Syst Rev. 2011 Mar 16;(3):CD006768
pubmed: 21412896
Invest Ophthalmol Vis Sci. 2013 Jun 14;54(6):4122-35
pubmed: 23674758
Vision Res. 2011 Aug 15;51(16):1845-52
pubmed: 21745493
Arch Ophthalmol. 2005 Jan;123(1):14-24
pubmed: 15642806
J Neurophysiol. 1992 Nov;68(5):1624-41
pubmed: 1479435
Optom Vis Sci. 2005 Jul;82(7):583-95
pubmed: 16044063
Vision Res. 2012 Jun 15;63:9-19
pubmed: 22575337
Optom Vis Sci. 1991 Jun;68(6):441-51
pubmed: 1891195
Arch Ophthalmol. 2008 Oct;126(10):1336-49
pubmed: 18852411

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH